Phytotherapy Research最新文献

Crohn's disease (CD), a chronic inflammatory bowel disease, is frequently complicated by intestinal fibrosis, a process driven by extracellular matrix remodeling. Current therapies lack efficacy in controlling or reversing fibrotic progression, underscoring the need for novel treatments. Here, we found that garlic-derived exosomes (GDE) significantly reduced hydroxyproline production and inhibited the expression of fibrosis-related proteins such as COL1A2, COL3A1, and α-SMA in TGF-β1-treated intestinal fibroblasts. Administration of GDE significantly improved the lesions of the muscular mucosa, the colon shortening, and bowel wall thickness, while also decreasing the expression of COL1A2, COL3A1, and α-SMA in the colon tissues of 2,4,6-trinitrobenzene sulfonic acid (TNBS)-induced mice. Meanwhile, GDE significantly attenuated phosphofructo-2-kinase/fructose-2, 6-bisphosphatase 3 (PFKFB3) expression in TGF-β1 treated intestinal fibroblasts and colon tissue of TNBS-induced mice. Both Pfkfb3 gene interruption and PFK-015 (a PFKFB3 inhibitor) markedly prevented the role of GDE in the expression of fibrosis-related biomarkers by blocking the glycolysis pathway and triggering metabolic reprogramming in TGF-β-treated intestinal fibroblasts. Furthermore, fibroblast-specific Pfkfb3 deficiency significantly reduced the fibrosis in the colon tissues of TNBS-induced mice. Taken together, this study reveals the anti-fibrotic mechanism of GDE by regulating Pfkfb3 expression to inhibit the metabolic reprogramming of fibroblasts, which is expected to provide new strategies and targets for the treatment of intestinal fibrosis in patients with CD.

Background: ALDH1A3 is a key factor associated with tumor stemness and chemotherapy resistance, making it a promising therapeutic target. Screening various compounds with potential inhibition of cancer stem cells led to the discovery of a naturally occurring Dioscin as a novel ALDH1A3 inhibitor. However, the precise mechanism underlying its action remains unexplored.

Experimental procedure: Immunohistochemical analysis of 90 ovarian serous tumor samples revealed the clinical significance of ALDH1A3 in tumor progression. TCGA data was used to identify genes highly correlated with ALDH1A3 in ovarian cancer. Using CRISPR/Cas9-generated ALDH1A3 knockout (KO) cell lines, we investigated its oncogenic influence in ovarian and gastric cancers. The anti-tumor effects of Dioscin were assessed through MTT, scratch, and 3D spheroid formation assays. In vivo efficacy of Dioscin was assessed using a xenograft mouse model. Mechanistic investigations of Dioscin with ALDH1A3 were predicted by molecular docking and assessed through ALDH1A3 enzymatic activity and retinoic acid (RA) metabolism analyses.

Results: ALDH1A3 expression correlates with early-stage ovarian cancer progression. Genetic ablation of ALDH1A3 significantly suppressed cell proliferation, migration, and stemness properties. ALDH1A3 is significantly associated with ECM-related genes in ovarian cancer. Dioscin exhibited an ALDH1A3-dependent anti-tumor effect by inhibiting ALDH1A3 enzymatic activity, disrupting RA metabolism, and downregulating the expression of stemness- and migration-associated proteins (CD44 and MMP2). Furthermore, Dioscin effectively delays tumor growth without obvious signs of toxicity.

Conclusion: Our study provides the first evidence that Dioscin inhibits ALDH1A3-mediated RA metabolism and cancer stemness. Our data will further support its potential as a therapeutic agent for cancer treatment.

Lung cancer (LC) remains the leading cause of global cancer-related death due to delayed diagnosis, poor therapeutic efficacy, and drug resistance. Traditional therapeutic methods like radiation, chemotherapy, and targeted medicines are often associated with high toxicity and often result in minimal survival improvements. Phytochemicals from medicinal plants are increasingly being considered as potential LC treatment agents due to their multi-targeted action, safety, and accessibility. These have anticancer properties by regulating key molecular signaling pathways like PI3K/Akt/mTOR, MAPK/ERK, NF-κB, STAT3, and apoptotic cascades. These compounds also promote apoptosis, increase chemotherapeutic medication sensitivity, and prevent tumor cell growth, angiogenesis, invasion, and metastasis. Phytochemicals have shown potential in reducing therapy-induced side effects and combating multidrug resistance, potentially enhancing treatment effectiveness. Despite promising discoveries, challenges such as low bioavailability, limited pharmacokinetic stability, and lack of extensive clinical validation inhibit their widespread use. This review provides clinical insights into phytochemical-based LC preventive and treatment approaches, focusing on their role in addressing molecular signaling pathways. It demonstrates the potential medicinal benefits, potential disadvantages, and potential applications of phytocompounds as supplementary or alternative treatments for LC.

Psychological stress (or simply "stress") is a major contributor to chronic disease worldwide, affecting 35% of the global population, including younger generations. Furthermore, it plays a significant role in human premature aging; hence, its detrimental effects on people's health compel us to comprehend and control the ways in which psychological stress impacts our bodies, including our skin. For example, flavonoids, a class of polyphenolic phytochemicals, are an important group of plant secondary metabolites and appear as a promising solution. These compounds exhibit a number of general biological activities, such as anti-inflammatory and antioxidant properties, as well as certain skin-specific ones, like wound healing, photoprotection, and the treatment of inflammatory and cancerous disorders associated with the skin. For this reason alone, flavonoids could be regarded as a promising solution. Further, these substances have demonstrated beneficial effects on the different hallmarks of aging, demonstrating their potential as anti-aging agents. They also have the ability to influence hormones linked to stress, which, considering their effects on skin health and aging mechanisms, seems to suggest that flavonoids may be effective ways to mitigate the negative effects of stress on premature skin aging. Therefore, this review seeks to demonstrate the potential of flavonoids as potential anti-aging agents for the skin, either by improving the so-called hallmarks of aging or by directly protecting the skin from external aggressors like UV radiation while reducing the negative effects of psychological stress and its known mediators.

As the global population ages, the incidence of Alzheimer's disease (AD) increases, burdening patients, families, and society. In recent years, microglia have been shown to interact with T cells, astrocytes, and other immune cells to form a complex immune microenvironment, which plays a damaging or protective role on neurons during the pathological process of AD. Herein, we review the interactions between microglia and other immune cells in the pathogenesis of AD and explore the potential of natural compounds as multi-targeted therapeutic strategies: (1) Balancing glial cell polarization status and ameliorating neuroinflammation by inhibiting core neuroinflammatory pathways such as NF-κB (nuclear factor kappa-B), MAPK, and NLRP3 inflammasome; (2) modulating the gut flora-brain axis function to inhibit central inflammation indirectly; (3) multi-targeted interventions for core AD pathology, including amyloid-beta (Aβ) clearance, tau phosphorylation, and synaptic plasticity. However, natural compounds still face clinical translation bottlenecks such as low bioavailability and poor blood-brain barrier permeability. Current studies have shown that nanocarrier systems and combination therapy strategies hold promise for addressing existing bottlenecks. However, systematic validation is still required for their clinical translation. This review systematically summarizes progress in the treatment of AD by regulating microglia and other immune cell interactions using natural compounds.

Herbal remedies are increasingly adopted as alternatives to conventional pharmacological treatments, particularly among women seeking natural approaches to managing menopausal symptoms. This interest is driven by perceptions of greater safety, affordability, and fewer adverse effects associated with medicinal plants. Vitex agnus-castus (VAC), commonly known as chaste tree, is one of the most widely utilized botanical agents for women's health. VAC is rich in diverse bioactive constituents, including flavonoids, iridoids, diterpenes, and essential oils, which collectively contribute to its complex pharmacological profile. Emerging evidence from in vitro, in vivo, and clinical studies suggests that VAC may modulate key neuroendocrine pathways involved in menopause through dopaminergic, phytoestrogenic, opioidergic, and indirect serotonergic mechanisms. These actions are proposed to influence prolactin regulation, estrogen receptor activity, mood stability, vasomotor symptoms, and overall hormonal balance during the menopausal transition. This review synthesizes current knowledge on the phytochemical composition and mechanistic pathways of VAC relevant to menopausal symptom management, alongside an evaluation of its safety and clinical tolerability. Although VAC extracts appear generally safe, effective, and well tolerated, further research is needed to clarify molecular targets, determine optimal dosing strategies, identify responsive patient subgroups, and standardize outcome measures to strengthen evidence-based clinical use.

Atherosclerosis (AS) constitutes the pathological basis of multiple cardiovascular diseases, predisposing to severe clinical complications. Isorhynchophylline (IRN), a principal bioactive alkaloid derived from Uncaria rhynchophylla, exhibits anti-inflammatory properties, yet its therapeutic potential and molecular mechanisms in AS remain unexplored. Scratch wound healing and Transwell migration assays were conducted to evaluate the effects of monomer compounds on cellular migratory and invasive capabilities. The changes in mRNA and protein expression levels of inflammation genes were determined using RT-PCR and western blot analyses, respectively. Molecular docking and drug affinity responsive target stability analyses were performed to assess the binding affinity of IRN and PP2AC. Our findings demonstrate that IRN treatment effectively ameliorates atherosclerotic plaque progression and mitigates endothelial inflammation. The underlying mechanism involves the binding of IRN to PP2AC and the subsequent regulation of YAP activity. This study underscores the therapeutic potential of IRN in alleviating inflammation and its promise as a treatment for AS.

Hepatic ferroptosis has emerged as a crucial pathogenic mechanism and severe adverse outcome in metabolic-associated fatty liver disease (MAFLD). Curcumol (CCM), a sesquiterpenoid phytochemical with potential hepatoprotective properties, remains unexplored for its therapeutic properties in MAFLD management. In this study, the effects and mechanisms of CCM on hepatic ferroptosis in MAFLD were investigated using in silico approaches and evaluated at the cellular and molecular levels using both in vivo and in vitro disease models of MAFLD. Our results showed that hepatic ferroptosis was accompanied by endoplasmic reticulum stress (ERS) in high-fat-induced MAFLD. Administration of the ERS inhibitor 4-PBA significantly alleviated ferroptosis, suggesting the pathogenic role of ERS-mediated ferroptosis in MAFLD. Notably, CCM exhibited comparable effects to 4-PBA, indicating that CCM mitigated hepatic ferroptosis through inhibiting ERS. Subsequent data showed that the therapeutic effects of CCM were achieved by targeting epidermal growth factor receptor (EGFR), as evidenced by the phenomenon that the efficacy of CCM was reversed following the administration of an EGFR agonist. In conclusion, this study highlighted the therapeutic effects of CCM on alleviating hepatic ferroptosis in high-fat-induced MAFLD by inhibiting the EGFR-ERS axis, and emphasized the promising application of CCM in MAFLD management.

Overexpression of P-glycoprotein (P-gp) in non-small cell lung cancer (NSCLC) cells is one of the primary causes of multidrug resistance (MDR), but the molecular mechanism remains obscure. Murine double minute 2 (MDM2) has been implicated in drug resistance across multiple cancer types. In this study, we investigated the potential mechanism of MDM2 on P-gp-mediated MDR of NSCLC and explored the potential therapeutic effects of 20(R)-ginsenoside Rg3 (Rg3). Western blot, RT-PCR, and immunohistochemistry (IHC) were applied to analyze the expression of critical signaling markers. The drug accumulation in resistant cells was measured using flow cytometry and confocal microscopy. Bioinformatics analysis, co-immunoprecipitation (co-IP), and immunofluorescence were conducted to confirm the protein-protein interactions. MTT, colony formation, EdU, and in vivo cell line derived xenograft (CDX) models were applied to validate therapeutic agents and molecular mechanisms. We demonstrated that MDM2 acted as a positive upstream regulator of P-gp, and the inhibition of MDM2 by Rg3 increased the sensitivity of resistant cells to taxol treatment both in vivo and in vitro. Mechanistically, we uncovered that MDM2 bound to IκB-α, facilitating its ubiquitination degradation, which subsequently promoted NF-κB pathway activation to drive the high expression of P-gp. Notably, Rg3 blocked this process by inhibiting MDM2. Moreover, interference with the NF-κB pathway reversed the regulation of P-gp expression by MDM2. Our findings elucidate the molecular mechanisms of Rg3 in the treatment of P-gp-mediated MDR in NSCLC. This study also provides a new strategy to overcome P-gp-mediated MDR by inhibiting the MDM2-IκB-α signaling axis.

Fibroblast-like synoviocytes (FLS) drive rheumatoid arthritis (RA) progression. Bacopaside I (BSI), a major component of the anti-RA herb Bacopa monnieri, demonstrates anti-arthritic effects in RA animal models; however, its precise anti-rheumatic mechanisms, especially regarding suppression of RA-FLS pathogenicity, remain unclear. Collagen-induced arthritis (CIA) rats and TNF-α-stimulated RA-FLS were used as in vivo and in vitro models of RA. We studied BSI's therapeutic potential in CIA rats and its influences on TNF-α-induced migration, invasion, and inflammation in RA-FLS, focusing on the underlying mechanism of Wnt/β-catenin pathway inhibition. BSI exhibited arthritis-alleviating activity in CIA rats, as evidenced by reductions in paw swelling, arthritis index, and histological damage to ankle joints. It also decreased serum and synovial levels of IL-1β, IL-6, and TNF-α, indicating anti-inflammatory effects in vivo. At non-cytotoxic concentrations, BSI inhibited migration, invasion, and F-actin remodeling in TNF-α-stimulated RA-FLS. Similar to its anti-inflammatory activity in vivo, BSI decreased pro-inflammatory factor production in vitro, including IL-1β, IL-6, IL-8, MMP-2, and MMP-9. Mechanistically, BSI treatment inhibited Wnt/β-catenin pathway activation in both CIA rat synovium and TNF-α-stimulated RA-FLS, as demonstrated by decreased Wnt1, p-GSK-3β (Ser9), and β-catenin protein levels, increased p-β-catenin, reduced β-catenin nuclear translocation, and a lower TOP/FOP ratio. Importantly, the critical involvement of this pathway was further confirmed by the loss of BSI's benefits following β-catenin overexpression in TNF-α-stimulated RA-FLS. BSI ameliorates arthritis severity and RA-FLS pathogenicity by suppressing the Wnt/β-catenin pathway, highlighting its promise as a novel candidate for RA treatment.